On this page:
An analysis of two pooled studies in early-stage ovarian cancer showed an increase in overall survival with the administration of chemotherapy. Guidelines suggest intraperitoneal (IP) chemotherapy for later stage ovarian cancer.
Percentage of individuals diagnosed with ovarian cancer who received chemotherapy by stage of diagnosis.
In 2002, 56 percent of women with stage I or II ovarian cancer received chemotherapy compared to 72 percent of women with stage III or IV disease. An NCI patterns of care study of ovarian cancer is being planned for 2013.
There are no Healthy People targets for cancer treatment, including for ovarian cancer treatment.
Paclitaxel is recommended for the treatment of ovarian cancer. There has been a non-significant decrease in its use for women with stage III or IV disease between 1996 and 2002.
Taxol was approved for the treatment of ovarian cancer in December 1992. Between 1991 and 1996, the dissemination of taxol into community practice can be seen. There was a substitution of taxol for cyclophosphamide in those years.
The use of IP chemotherapy is recommended for late-stage ovarian cancer. Research is needed to examine the current use of IP therapy.